About: AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $11.46 (+0.79%)
ABCL NASDAQ Abcellera Biologics Inc
Abcellera Biologics Inc share price
Atividade de preço de ABCL
Último preço
$ 11,460
Variação (24h)
0,09 USD (0,79%)
Volume
906.60K
Volume (média 4 sem.)
-
Abertura
$ 11,45
Variação do dia
$ 11,08 - $ 11,51
Fechamento anterior
$ 11,37
Último negócio
23 Oct, 2:43 pm GMT+0
Atrasado
23 Oct, 2:43 pm GMT+0
ABCL price performance
Atrasado
23 Oct, 2:43 pm GMT+0
quote.marketSignals